We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
-10.3%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$3.69B
AUM Growth
-$784M
Cap. Flow
+$36.9M
Cap. Flow %
1%
Top 10 Hldgs %
43.31%
Holding
160
New
14
Increased
20
Reduced
11
Closed
10

Top Buys

Rank Stock Value
1
EQRX
EQRx, Inc. Common Stock
EQRX
+$37.8M
2
KYMR icon
Kymera Therapeutics
KYMR
+$34.9M
3
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$31.1M
4
EVO icon
Evotec
EVO
+$26.8M
5
BLU
BELLUS Health Inc.
BLU
+$21.6M

Top Sells

Rank Stock Value
1
XLRN
Acceleron Pharma
XLRN
+$172M
2
ARGX icon
argenx
ARGX
+$23.5M
3
ITOS
iTeos Therapeutics
ITOS
+$15M
4
BABA icon
Alibaba
BABA
+$14.8M
5
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$14.1M

Sector Composition

Rank Sector Weight
1 Healthcare 83.88%
2 Miscellaneous 7.67%
3 Consumer Discretionary 6.51%
4 Financials 0.7%
5 Materials 0.5%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OPTU
151
Optimum Communications Inc
OPTU
$377M
– –
-27,000
Closed -$559K
AVTR icon
152
Avantor
AVTR
$10.4B
– –
-50,000
Closed -$2.04M
BABA icon
153
Alibaba
BABA
$272B
– –
-100,000
Closed -$14.8M
BPMC
154
DELISTED
Blueprint Medicines
BPMC
– –
-100,000
Closed -$10.3M
EQT icon
155
EQT Corp
EQT
$33.2B
– –
-9,678
Closed -$198K
FCX icon
156
CALL
Freeport-McMoran
FCX
$99.6B
– –
-3,500,000
Closed -$114M
MRK icon
157
CALL
Merck
MRK
$355B
– –
-500,000
Closed -$37.6M
OLPX
158
DELISTED
Olaplex Holdings
OLPX
– –
-225,000
Closed -$5.51M
DRNA
159
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
– –
-700,000
Closed -$14.1M
XLRN
160
DELISTED
Acceleron Pharma
XLRN
– –
-1,000,000
Closed -$172M
3 4 5 6
7

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $931M AUM 47.97% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $931M AUM 4.95% 1-Year Est. Return
SAM
Sycomore Asset Management Paris, France $932M AUM 51.25% 1-Year Est. Return
NS
Night Squared New York $930M AUM 56.46% 1-Year Est. Return
PA
Planning Alternatives Birmingham, Michigan $933M AUM 28.32% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $933M AUM 56.2% 1-Year Est. Return
CICI
Capital Investment Counsel Inc Raleigh, North Carolina $929M AUM 53.07% 1-Year Est. Return
CAM
Claret Asset Management Montreal, Quebec, Canada $928M AUM 25.4% 1-Year Est. Return

Artal Group's Q4 2021 Portfolio in Review

As of Q4 2021, Artal Group held 160 positions worth $3.69B, down 18% from $4.47B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Artal Group's Q4 2021 filing shows 14 new, 20 increased, 11 reduced and 10 closed positions. Its largest new stake was EQRx, Inc. Common Stock: 4,000,000 shares worth $27.3M. The largest sale was Acceleron Pharma, an estimated $172M.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, up from 83% a quarter earlier, followed by Miscellaneous and Consumer Discretionary.

  • Artal Group's largest Q4 2021 buy was EQRx, Inc. Common Stock: 4,000,000 shares worth $27.3M.
  • Artal Group added most to Kymera Therapeutics in Q4 2021, an estimated $34.9M increase.
  • Artal Group's biggest Q4 2021 reduction was argenx, cutting an estimated $23.5M.
  • Artal Group fully exited Acceleron Pharma in Q4 2021, selling an estimated $172M.
  • Artal Group's ten largest holdings make up 43% of its $3.69B portfolio in Q4 2021.
  • Artal Group opened 14 new positions and closed 10 in Q4 2021.
  • Artal Group's portfolio value fell 18% quarter-over-quarter to $3.69B.

Based on Artal Group's 13F filing for Q4 2021, filed 11 Feb 2022.